ALPHA-1 ANTI-TRYPSIN DEFICIENCY

Clinical trials for ALPHA-1 ANTI-TRYPSIN DEFICIENCY explained in plain language.

Never miss a new study

Get alerted when new ALPHA-1 ANTI-TRYPSIN DEFICIENCY trials appear

Sign up with your email to follow new studies for ALPHA-1 ANTI-TRYPSIN DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

First test of new genetic therapy for rare lung disease

Disease control Ongoing

This is the first human study of an experimental drug called KRRO 110 for Alpha-1 antitrypsin deficiency (AATD), a genetic condition that can cause lung and liver disease. The trial will test single and multiple doses in 64 healthy volunteers and people with AATD to check safety,…

Matched conditions: ALPHA-1 ANTI-TRYPSIN DEFICIENCY

Phase: PHASE1, PHASE2 • Sponsor: Korro Bio, Inc. • Aim: Disease control

Last updated Mar 23, 2026 15:19 UTC

ALPHA-1 ANTI-TRYPSIN DEFICIENCY

Get alerted when new ALPHA-1 ANTI-TRYPSIN DEFICIENCY trials appear

First test of new genetic therapy for rare lung disease